Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1980 Mar;21(3):225-33.
doi: 10.1016/0010-7824(80)90003-7.

Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD

Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD

C G Nilsson et al. Contraception. 1980 Mar.

Abstract

Plasma concentrations of levonorgestrel, progesterone, estradiol, FSH and LH were measured in seven volunteers who had a levonorgestrel-releasing IUD inserted postmenstrually. Blood samples were collected twice weekly during a mean of 93 days immediately postmenstrually and during a mean of 41 days over the twelfth to fifteenth month of treatment. Patterns of bleeding were studied during the first year of treatment. The IUDs used were designed to release 25 micrograms/day of levonorgestrel. The mean +/- SD plasma concentration of levonorgestrel for all subjects during the first three months was 260 +/- 68 pg/ml, and 129 +/- 28 pg/ml after one year of treatment. During the initial period of blood sampling only two of the subjects ovulated, while only two did not ovulate after one year of treatment. Intermenstrual spotting occurred during the first sixty days of treatment. Three subjects developed amenorrhea at the end of the first year. All the subjects continued the use of the IUD and no pregnancies occurred.

PIP: Steroid profiles of women wearing levonorgestrel-containing IUDs during the first 3 months of treatment were compared with those from the same subject after 1 year of treatment. Bleeding patterns were also studied in the 7 volunteers in this study. Plasma concentrations of levonorgestrel, progesterone, estradiol, follicle stimulating hormone, and luteinizing hormone were assayed in blood samples collected 2 times/week during a mean of 93 days immediately postmenstrually and during a mean of 41 days over the 12th-15th month of treatment. The medicated IUDs were designed to release 25 mcg of steroid per day. Steroid profiles showed that during the initial period of blood sampling only 2 subjects ovulated, but by 1 year only 2 of 7 had not ovulated. Levonorgestrel concentrations (mean) were 260+ or -68 pg/ml during the first 3 months and 129+ or -28 pg/ml at the end of 1 year of treatment. After the 1-year trial, all subjects continued using the medicated IUD and no pregnancies have occurred. Bleeding side effects were mostly spotting and intermenstual bleeding during the first 60 days of treatment; however, 3 subjects had developed amenorrhea by the end of the first year of treatment.

PubMed Disclaimer

Similar articles

Cited by

LinkOut - more resources